About Us:
Structure Therapeutics develops life‐changing medicines for patients using advanced structure‐based and computational drug discovery technology. The company’s platform combines the latest advancements in visualization of molecular interactions, computational chemistry, and data integration to design orally available, superior small molecule medicines that overcome current limitations of biologic and peptide drugs. We are advancing a clinical‐stage pipeline of differentiated treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic, and pulmonary conditions.
Structure Therapeutics is led by an experienced group of international drug innovators and financed by top-tier global life sciences investors. The company completed an initial public offering (IPO) in February 2023. With offices in California and Shanghai, Structure Therapeutics has the benefit of being at the center of life science innovation in both the US and China and capitalizing on the strengths of each geographic location.
Position Summary:
This position will be responsible for the internal and external activities associated with characterizing the preclinical ADME/PK aspects of specific programs in preclinical development, including selection and supervision of CRO, providing PK, in vitro/in vivo drug metabolism and PK/PD modeling and analysis support, study planning and execution, interpretation of pharmacokinetic and ADME data, contributor to relevant sections of regulatory documents including IND or IMPD submissions, briefing packages or background documents and NDA or MAA submissions, supporting clinical pharmacology trial design based on DDI risk analysis based on nonclinical data.
Job Responsibilities:
Qualifications:
Job details are sourced from the employer's original posting.
Open job postingAbout the company
Structuretx is a clinical research organization (CRO) that provides services for clinical trial management. They focus on drug development and adhere to ICH guidelines/GCP.